

Market Analysis of 19th Annual Summit on Surgical Oncology

Giuseppe Musumeci

The global cancer profiling market was valued at \$13.30 billion in 2012. Global oncology consuming hit \$91 billion for 2013 and it's expanding at a 5% clip annually, which will cross \$100 billion in 2015.

The **Worldwide Oncology** Information System Market place is to to expand powerfully during the estimated period 2017 to 2027. Some of the prominent trends that the market observing include growing availability of a variety of cancer therapies, like, increase in technological advancements like chemotherapy and radiation therapy incorporation of patient portals and increasing initiatives related to innovation of healthcare infrastructure.

Surgical Oncology, to put simply is the study of cancer- its causes, its symptoms, diagnosis, and treatment. Detection of cancer is not as complicated as it used to be because of oncology, and this branch aims to educate people about the potential dangers of this disease and how as a society, humans can take small steps towards eliminating it. Home to the eminent Cancer Research Institute, a US-based non-beneficial organization, North America was the geographical leader of the global oncology market. In 2018 , it held a country market share of 46%. There are different types of oncology involving medical oncology which makes the use of medicines or chemotherapy, surgical oncology, in which the surgeon removes the tumour from the tissue and radiation oncology which utilizes radiation therapy. The application sector of chemotherapy is estimated to enlarge at an remarkable CAGR of 13.6 % during the forecast period of 2019-2025.


The key players in the cancer profiling market are Boreal Genomics Inc. (U.K.), Precision Therapeutics Inc. (U.S.), bioTheranostics (U.S.), Proteome Sciences PLC (U.K.), Agendia (The Netherlands), Nanostring Technologies (U.S.), (U.S.), Caris Life Sciences (U.S.), Genomic Health Inc. (U.S.), Illumina Inc. (U.S.), Oxford Gene Technology Ltd. Rational Therapeutics (U.S.), Life Technologies Corporation (U.S.), NeoGenomics Laboratories (U.S.), Oncopath Laboratories (U.S.), and RiboMed Biotechnologies Inc. (U.S.).

Global cancer diagnostics market is expected to achieve \$13.1 Billion in 2020 from an estimated \$7.1 Billion in 2015, growing at a CAGR of 12.9%. The market is governed by Europe, Asia , North America and Rest of the World (RoW).

The cancer diagnostics market in Asia is expected to develop at the maximum rate from 2015 to 2020. According to the market the global oncology drugs market is expected to reach at \$111.9 billion by 2020.

The Clear conclusion of crucial cancer drugs such as Herceptin, Erbitux, Rituxan and Avastin, is supposed to boost the increase of cancer biosimilars market by 2020.

Cancer Therapy Market - Revenue Share (%), By Therapy Type, Global, 2018



About 12.7 million of people with cancer cases and 7.6 million cancer deaths are estimated to have happened in 2008 worldwide, with 56% of the cases and 64% of the deaths in the economically developing world.

For more details about the conference:
<http://surgicaloncology.alliedacademies.com/>

Contacts:

Amy Florence
Program Manager | Surgical Oncology 2020
Phone: (44) 203 769 1755
WhatsApp: (44) 330 808 0104

Giuseppe Musumeci

Department of Human Anatomy, University of Catania, Catania, Italy, E-mail: giumusu@gmail.com